Exelixis Inc.

Money comes mostly from direct sales of a single approved cancer drug, booked as revenue once it reaches distributors, plus a smaller stream of licensing fees, milestones and royalties from partner companies developing or selling related products elsewhere. Across the run of annual results CompanyGraph holds, that combination has produced positive net income every year, with margins and cash generation toward the high end of its industry peers.

Because it owns none of the plants that make its product and contracts manufacturing out instead, added sales of its approved drug convert into profit and cash at a rate toward the high end of its industry peers on gross margin, operating margin, cash conversion and returns on assets and equity, with elevated asset turnover alongside elevated returns suggesting this reflects more than just borrowed money. This fits the wider pattern common to drug development that depends on clearing a regulatory approval gate, where cost concentrates upfront and each additional sale after approval adds comparatively little further capital cost.

The company depends on outside suppliers spread across multiple world regions for raw drug material, and on outside contract manufacturers for every step of turning that material into a finished drug, since it owns no manufacturing facilities of its own. It also depends on international partners to sell its main drug outside the United States, on collaboration partners to advance its pipeline, on continued patent protection, regulatory approval and payer coverage for its revenue, and on its ability to recruit and retain skilled staff.

A mix of large pharmaceutical distributors, specialty pharmacies, government health-purchasing programs, group-purchasing organizations and health plans buy the drug from the company and resell it to healthcare providers and patients, while international partner companies depend on it for continued supply of the drug they sell in their own territories. Healthcare providers and the patients being treated for the cancers its drug targets are the ultimate recipients in that chain and depend on continued access to it.

The company points to its patent portfolio and to clinical trial results for its main drug, along with its research and recruiting capability, as what sets it apart from rival treatments; these are the company's own claims about its position, not something measured independently here. Separately, the basic shape of its business, developing drugs that earn nothing until they clear a regulatory approval gate, is shared by a large number of other companies, so that structure alone does not distinguish it from peers.

In its own filings, the company points to a specific set of things that limit how much it can grow: whether its existing main drug keeps selling well, whether it can win additional approvals and get its pipeline of newer drugs through development, whether payers continue to reimburse for treatment, whether it can keep its patents intact against challengers, its own capacity to manufacture and commercialize products, its access to capital, and its ability to recruit and retain skilled staff.

Nearly all of the money it earns traces back to a single drug, so anything that weakens that drug's sales, a loss of patent protection, a successful generic or follow-on competitor, an adverse coverage or reimbursement decision by payers, or a new competing therapy, would have an outsized effect on the whole company. Its patents on that drug are the kind of legal protection that rival manufacturers can and do challenge, requiring it to defend them through litigation, and it separately relies on partner companies to sell the same drug outside the United States and on outside contract manufacturers to make it.

Regulators that must approve any new drug or new use before it can be sold act as a recurring check on growth, alongside separate agencies overseeing workplace and environmental compliance, patent challenges from rival manufacturers seeking to sell equivalent versions of its main drug, and proposed tariffs on imported pharmaceutical raw materials and components. Healthcare payers and drug-pricing rules act as a further outside constraint on how much revenue it can realize even after approval, and currency movements in the euro and yen affect the value of royalty income earned abroad.